Treatment of Friedreich's ataxia

Expert Opinion on Orphan Drugs

Volumn 1, Issue 3, 2013, Pages 221-234

  Pandolfo, Massimo ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Animal models; Antioxidants; Cellular models; Clinical trial design; Epigenetic silencing; Friedreich's ataxia; Histone deacetylase inhibitors; Iron chelators; Iron metabolism; Mitochondrial dysfunction

Indexed keywords

A 0001; ALPHA TOCOPHEROL; ALPHA TOCOPHERYLQUINONE; BIOLOGICAL MARKER; CARNITINE; CREATINE; DEFERIPRONE; DEFEROXAMINE; FRATAXIN; HISTONE DEACETYLASE INHIBITOR; IDEBENONE; IRON CHELATING AGENT; RECOMBINANT ERYTHROPOIETIN; UBIDECARENONE; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; CLINICAL ASSESSMENT TOOL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG SAFETY; EPIGENETICS; FRATAXIN GENE; FRIEDREICH ATAXIA; GENE; GENE EXPRESSION; GENE INDUCTION; GENE MUTATION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; IRON METABOLISM; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT;

EID: 84896691710     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2013.771578     Document Type: Review

References (105)

1. Harding AE. Friedreichs ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 1981;104:589-620
2. Koeppen AH. Friedreichs ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci 2011;303:1-12
3. Pandolfo M. Friedreich ataxia: the clinical picture. J Neurol 2009;256(Suppl 1):3-8
4. Rance G, Corben L, Barker E, et al. Auditory perception in individuals with Friedreichs ataxia. Audiol Neurootol 2010;15:229-40
5. Payne RM, Wagner GR. Cardiomyopathy in friedreich ataxia: clinical findings and research. J Child Neurol 2012;27:1179-86
6. Bourke T, Keane D. Friedreichs ataxia: a review from a cardiology perspective. Ir J Med Sci 2011;180:799-805
7. Tsou AY, Paulsen EK, Lagedrost SJ, et al. Mortality in Friedreich ataxia. J Neurol Sci 2011;307:46-9
8. Cnop M, Igoillo-Esteve M, Rai M, et al. The central role and mechanisms of beta-cell dysfunction and death in Friedreichs ataxia-associated diabetes. Ann Neurol 2012;72(6):971-82
9. Campuzano V, Montermini L, Molto MD, et al. Friedreichs ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996;271:1423-7
10. Montermini L, Andermann E, Labuda M, et al. The Friedreich ataxia GAA triplet repeat: premutation and normal alleles. Hum Mol Genet 1997;6:1261-6
11. Cossee M, Schmitt M, Campuzano V, et al. Evolution of the Friedreichs ataxia trinucleotide repeat expansion: founder effect and premutations. Proc Natl Acad Sci USA 1997;94:7452-7
12. Montermini L, Kish SJ, Jiralerspong S, et al. Somatic mosaicism for Friedreichs ataxia GAA triplet repeat expansions in the central nervous system. Neurology 1997;49:606-10
13. De Biase I, Rasmussen A, Endres D, et al. Progressive GAA expansions in dorsal root ganglia of Friedreichs ataxia patients. Ann Neurol 2007;61:55-60
14. Durr A, Cossee M, Agid Y, et al. Clinical and genetic abnormalities in patients with Friedreichs ataxia. N Engl J Med 1996;335:1169-75
15. Montermini L, Richter A, Morgan K, et al. Phenotypic variability in Friedreich ataxia: role of the associated GAA triplet repeat expansion. Ann Neurol 1997;41:675-82
16. Filla A, De Michele G, Cavalcanti F, et al. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet 1996;59:554-60
17. Saveliev A, Everett C, Sharpe T, et al. DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature 2003;422:909-13
18. Herman D, Jenssen K, Burnett R, et al. Histone deacetylase inhibitors reverse gene silencing in Friedreichs ataxia. Nat Chem Biol 2006;2:551-8
19. Campuzano V, Montermini L, Lutz Y, et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 1997;6:1771-80
20. Deutsch EC, Santani AB, Perlman SL, et al. A rapid, noninvasive immunoassay for frataxin: utility in assessment of Friedreich ataxia. Mol Genet Metab 2010;101:238-45
21. Cossee M, Durr A, Schmitt M, et al. Friedreichs ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol 1999;45:200-6
22. Zuhlke CH, Dalski A, Habeck M, et al. Extension of the mutation spectrum in Friedreichs ataxia: detection of an exon deletion and novel missense mutations. Eur J Hum Genet 2004;12:979-82
23. Stemmler TL, Lesuisse E, Pain D, Dancis A. Frataxin and mitochondrial FeS cluster biogenesis. J Biol Chem 2010;285:26737-43
24. Schmucker S, Martelli A, Colin F, et al. Mammalian frataxin: an essential function for cellular viability through an interaction with a preformed ISCU/NFS1/ISD11 iron-sulfur assembly complex. PLoS ONE 2011;6:e16199
25. Pandolfo M, Pastore A. The pathogenesis of Friedreich ataxia and the structure and function of frataxin. J. Neurol 2009;256(Suppl 1):9-17
26. Tsai C-L, Barondeau DP. Human frataxin is an allosteric switch that activates the Fe-S cluster biosynthetic complex. Biochemistry 2010;49:9132-9
27. Sheftel A, Stehling O, Lill R. Iron-sulfur proteins in health and disease. Trends Endocrinol Metab 2010;21:302-14
28. Vaubel RA, Isaya G. Iron-sulfur cluster synthesis, iron homeostasis and oxidative stress in Friedreich ataxia. Mol Cell Neurosci 2012; Epub ahead of print
29. Rouault TA. Biogenesis of iron-sulfur clusters in mammalian cells: new insights and relevance to human disease. Dis Model Mech 2012;5:155-64
30. Rotig A, de Lonlay P, Chretien D, et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 1997;17:215-17
31. Kakhlon O, Manning H, Breuer W, et al. Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. Blood 2008;112:5219-27
32. Armstrong JS, Khdour O, Hecht SM. Does oxidative stress contribute to the pathology of Friedreichs ataxia? A radical question. FASEB J 2010;24:2152-63
33. Lill R, Hoffmann B, Molik S, et al. The role of mitochondria in cellular iron-sulfur protein biogenesis and iron metabolism. Biochim Biophys Acta 2012;1823:1491-508
34. Lobmayr L, Brooks DG, Wilson RB. Increased IRP1 activity in Friedreich ataxia. Gene 2005;354:157-61
35. Piemonte F, Pastore A, Tozzi G, et al. Glutathione in blood of patients with Friedreichs ataxia. Eur J Clin Invest 2001;31:1007-11
36. Auchere F, Santos R, Planamente S, et al. Glutathione-dependent redox status of frataxin-deficient cells in a yeast model of Friedreichs ataxia. Hum Mol Genet 2008;17:2790-802
37. Sparaco M, Gaeta LM, Santorelli FM, et al. Friedreichs ataxia: oxidative stress and cytoskeletal abnormalities. J Neurol Sci 2009;287:111-18
38. Mochel F, Knight MA, Tong WH, et al. Splice mutation in the iron-sulfur cluster scaffold protein ISCU causes myopathy with exercise intolerance. Am J Hum Genet 2008;82:652-60
39. Navarro-Sastre A, Tort F, Stehling O, et al. A fatal mitochondrial disease is associated with defective NFU1 function in the maturation of a subset of mitochondrial Fe-S proteins. Am J Hum Genet 2011;89:656-67
40. Cossee M, Puccio H, Gansmuller A, et al. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum Mol Genet 2000;9:1219-26
41. Gonzalez-Cabo P, Llorens JV, Palau F, Molto MD. Friedreich ataxia: an update on animal models, frataxin function and therapies. Adv Exp Med Biol 2009;652:247-61
42. Babcock M, de Silva D, Oaks R, et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 1997;276:1709-12
43. Puccio H. Multicellular models of Friedreich ataxia. J Neurol 2009;256(Suppl 1):18-24
44. Puccio H, Simon D, Cossee M, et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 2001;27:181-6
45. Simon D, Seznec H, Gansmuller A, et al. Friedreich ataxia mouse models with progressive cerebellar and sensory ataxia reveal autophagic neurodegeneration in dorsal root ganglia. J Neurosci 2004;24:1987-95
46. Puccio H. Conditional mouse models for Friedreich ataxia, a neurodegenerative disorder associating cardiomyopathy. Handb Exp Pharmacol 2007(178):365-75
47. Miranda CJ, Santos MM, Ohshima K, et al. Frataxin knockin mouse. FEBS Lett 2002;512:291-7
48. Al-Mahdawi S, Pinto RM, Varshney D, et al. GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. Genomics 2006;88:580-90
49. Santos MM, Ohshima K, Pandolfo M. Frataxin deficiency enhances apoptosis in cells differentiating into neuroectoderm. Hum Mol Genet 2001;10:1935-44
50. Calmels N, Schmucker S, Wattenhofer-Donze M, et al. The first cellular models based on frataxin missense mutations that reproduce spontaneously the defects associated with Friedreich ataxia. PLoS One 2009;4:e6379
51. Ku S, Soragni E, Campau E, et al. Friedreichs ataxia induced pluripotent stem cells model intergenerational GAA-TTC triplet repeat instability. Cell Stem Cell 2010;7:631-7
52. Liu J, Verma PJ, Evans-Galea MV, et al. Generation of induced pluripotent stem cell lines from Friedreich ataxia patients. Stem Cell Rev 2011;7:703-13
53. Hick A, Wattenhofer-Donze M, Chintawar S, et al. Induced pluripotent stem cell derived neurons and cardiomyocytes as a model for mitochondrial defects in Friedreichs ataxia. Dis Model Mech 2013;[Epub ahead of print]
54. Trouillas P, Takayanagi T, Hallett M, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 1997;145:205-11
55. Storey E, Tuck K, Hester R, et al. Inter-rater reliability of the International Cooperative Ataxia Rating Scale (ICARS). Mov Disord 2004;19:190-2
56. Ribai P, Pousset F, Tanguy M-L, et al. Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up. Arch Neurol 2007;64:558-64
57. Mariotti C, Solari A, Torta D, et al. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 2003;60:1676-9
58. Subramony SH, May W, Lynch D, et al. Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology 2005;64:1261-2
59. Schmitz-Hubsch T, Montcel du ST, Baliko L, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 2006;66:1717-20
60. Schmitz-Hubsch T, Coudert M, Bauer P, et al. Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms. Neurology 2008;71:982-9
61. Lynch DR, Farmer JM, Wilson RL, Balcer LJ. Performance measures in Friedreich ataxia: potential utility as clinical outcome tools. Mov Disord 2005;20:777-82
62. Selak MA, Lyver E, Micklow E, et al. Blood cells from Friedreich ataxia patients harbor frataxin deficiency without a loss of mitochondrial function. Mitochondrion 2011;11:342-50
63. Emond M, Lepage G, Vanasse M, Pandolfo M. Increased levels of plasma malondialdehyde in Friedreich ataxia. Neurology 2000;55:1752-3
64. Schulz JB, Dehmer T, Schols L, et al. Oxidative stress in patients with Friedreich ataxia. Neurology 2000;55:1719-21
65. Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreichs ataxia: a randomised, placebo-controlled trial. Lancet Neurol 2007;6:878-86
66. Coppola G, Burnett R, Perlman S, et al. A gene expression phenotype in lymphocytes from Friedreich ataxia patients. Ann Neurol 2011;70:790-804
67. Lodi R, Cooper JM, Bradley JL, et al. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc Natl Acad Sci USA 1999;96:11492-5
68. Rizzo G, Tonon C, Valentino ML, et al. Brain diffusion-weighted imaging in Friedreichs ataxia. Mov Disord 2011;26:705-12
69. Vanasse M, Garcia-Larrea L, Neuschwander P, et al. Evoked potential studies in Friedreichs ataxia and progressive early onset cerebellar ataxia. Can J Neurol Sci 1988;15:292-8
70. Cruz-Martinez A, Palau F. Central motor conduction time by magnetic stimulation of the cortex and peripheral nerve conduction follow-up studies in Friedreichs ataxia. Electroencephalogr Clin Neurophysiol 1997;105:458-61
71. Santoro L, Perretti A, Lanzillo B, et al. Influence of GAA expansion size and disease duration on central nervous system impairment in Friedreichs ataxia: contribution to the understanding of the pathophysiology of the disease. Clin Neurophysiol 2000;111:1023-30
72. Hebert MD, Whittom AA. Gene-based approaches toward Friedreich ataxia therapeutics. Cell Mol Life Sci 2007;64:3034-43
73. McCown TJ. Adeno-Associated Virus (AAV) Vectors in the CNS. Curr Gene Ther 2011;11:181-8
74. Vyas PM, Tomamichel WJ, Pride PM, et al. A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreichs ataxia mouse model. Hum Mol Genet 2012;21:1230-47
75. Gottesfeld JM, Pandolfo M. Development of histone deacetylase inhibitors as therapeutics for neurological disease. Future Neurol 2009;4:775-84
76. Xu C, Soragni E, Chou CJ, et al. Chemical probes identify a role for histone deacetylase 3 in Friedreichs ataxia gene silencing. Chem Biol 2009;16:980-9
77. Rai M, Soragni E, Jenssen K, et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS ONE 2008;3:e1958
78. Rai M, Soragni E, Chou CJ, et al. Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreichs ataxia patients and in a mouse model. PLoS One 2010;5:e8825
79. Sandi C, Pinto RM, Al-Mahdawi S, et al. Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Neurobiol Dis 2011;42:496-505
80. Sturm B, Stupphann D, Kaun C, et al. Recombinant human erythropoietin: effects on frataxin expression in vitro. Eur J Clin Invest 2005;35:711-17
81. Acquaviva F, Castaldo I, Filla A, et al. Recombinant human erythropoietin increases frataxin protein expression without increasing mRNA expression. Cerebellum 2008;7:360-5
82. Boesch S, Sturm B, Hering S, et al. B: Friedreichs ataxia: clinical pilot trial with recombinant human erythropoietin. Ann Neurol 2007;62:521-4
83. Boesch S, Sturm B, Hering S, et al. Neurological effects of recombinant human erythropoietin in Friedreichs ataxia: a clinical pilot trial. Mov Disord 2008;23:1940-4
84. Mariotti C, Fancellu R, Caldarazzo S, et al. Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial. Mov Disord 2012;27:446-9
85. Sturm B, Helminger M, Steinkellner H, et al. Carbamylated erythropoietin increases frataxin independent from the erythropoietin receptor. Eur J Clin Invest 2010;40:561-5
86. Ghazizadeh M. Cisplatin may induce frataxin expression. J Nihon Med Sch 2003;70:367-71
87. Steinkellner H, Scheiber-Mojdehkar B, Goldenberg H, Sturm B. A high throughput electrochemiluminescence assay for the quantification of frataxin protein levels. Anal Chim Acta 2010;659:129-32
88. Cotticelli MG, Rasmussen L, Kushner NL, et al. Primary and secondary drug screening assays for Friedreich ataxia. J Biomol Screen 2012;17:303-13
89. Rustin P, Munnich A, Rotig A. Quinone analogs prevent enzymes targeted in Friedreich ataxia from iron-induced injury in vitro. Biofactors 1999;9:247-51
90. Perlman SL. A review of friedreich ataxia clinical trial results. J Child Neurol 2012;27:1217-22
91. Di Prospero NA, Sumner CJ, Penzak SR, et al. Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia. Arch Neurol 2007;64:803-8
92. Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Arch Neurol 2010;67:941-7
93. Meier T, Perlman SL, Rummey C, et al. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreichs ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J Neurol 2012;259:284-91
94. Cooper JM, Schapira AHV. Friedreichs ataxia: coenzyme Q10 and vitamin E therapy. Mitochondrion 2007;7(Suppl):S127-35
95. Cooper JM, Korlipara LVP, Hart PE, et al. Coenzyme Q10 and vitamin E deficiency in Friedreichs ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol 2008;15:1371-9
96. Lynch DR, Willi SM, Wilson RB, et al. A0001 in Friedreich ataxia: biochemical characterization and effects in a clinical trial. Mov Disord 2012;27:1026-33
97. Sadun AA, Chicani CF, Ross-Cisneros FN, et al. Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathy. Arch Neurol 2012;69:331-8
98. Schols L, Zange J, Abele M, et al. L-carnitine and creatine in Friedreichs ataxia. A randomized, placebo-controlled crossover trial. J Neural Transm 2005;112:789-96
99. Marmolino D, Manto M, Acquaviva F, et al. PGC-1alpha down-regulation affects the antioxidant response in Friedreichs ataxia. PLoS ONE 2010;5:e10025
100. Boddaert N, Le Quan Sang KH, Rotig A, et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007;110:401-8
101. Seznec H, Simon D, Monassier L, et al. Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. Hum Mol Genet 2004;13:1017-24
102. Sohn Y-S, Breuer W, Munnich A, Cabantchik ZI. Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood 2008;111:1690-9
103. Velasco-Sanchez D, Aracil A, Montero R, et al. Combined therapy with idebenone and deferiprone in patients with Friedreichs ataxia. Cerebellum 2011;10:1-8
104. Koeppen AH, Mazurkiewicz JE. Friedreich ataxia: neuropathology revised. J Neuropathol Exp Neurol 2013;72:78-90
105. Lagedrost SJ, Sutton MS, Cohen MS, et al. Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA). Am Heart J 2011;161:639-45